8 completed, 6 terminated, 2 recruiting, 1 active not recruiting. 18 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 8, Terminated 6, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Camurati-Engelmann Syndrome: new trials by email Literature Review of Camurati-Engelmann Syndrome trials Research Report on Camurati-Engelmann Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Bicara Therapeutics | 160 | 2026-09-01 | 2026-10-13 |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Bicara Therapeutics | 650 | 2025-01-28 | 2026-10-02 |
| Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis | Phase 1 / Phase 2 | Completed | Ziauddin University | 30 | 2024-08-12 | 2025-05-02 |
| Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients Losartan 25 milligram capsule, Placebo - Radiation Induced Fibrosis | Phase 2 | Active not recruiting | Shaw Cancer Center | 43 | 2023-08-17 | 2026-06-18 |
| Assessment of Growth Factors Levels Associated with Wound Healing After Soft Tissue Crown Lengthening single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm, single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%. - Gingival Overgrowth | Phase 2 | Completed | Al-Azhar University | 80 | 2021-10-03 | 2025-02-04 |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Bintrafusp alfa (M7824) - Urothelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2020-10-26 | 2022-03-22 |
| Losartan to Improve Hip Microfracture Losartan, Placebo - Hip Osteoarthritis, Hip Impingement Syndrome | Phase 1 / Phase 2 | Terminated | Steadman Philippon Research Institute | 1 | 2020-08-07 | 2023-10-30 |
| Bioimaging Study of 89Zr-M7824 in NSCLC 89Zirconium-M7824, M7824 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Olivia Newton-John Cancer Research Institute | 5 | 2020-06-01 | 2023-01-17 |
| A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer LY3200882, Pembrolizumab - Advanced Cancer | Phase 1 / Phase 2 | Withdrawn | Eli Lilly and Company | 2019-12-05 | 2020-02-19 | |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) M7824 - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 159 | 2019-03-26 | 2023-10-25 |
| A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma LY2157299, Sorafenib, Placebo - Hepatocellular Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 132 | 2014-08-08 | 2022-02-25 |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer PF03446962 - Transitional Cell Carcinoma of Bladder | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 14 | 2012-03-01 | 2021-05-14 |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer Fresolimumab, Radiation Therapy - Metastatic Breast Cancer | Phase 2 | Completed | Weill Medical College of Cornell University | 23 | 2011-07-01 | 2019-03-05 |
| A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Pleneva TM BGC20-0134, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Boston Scientific Corporation | 173 | 2009-11-01 | 2022-06-03 |
| Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV - Glioblastoma, Anaplastic Astrocytoma | Phase 2 | Completed | Isarna Therapeutics GmbH | 141 | 2003-04-01 | 2013-12-03 |
| E-Selectin Nasal Spray to Prevent Stroke Recurrence E-Selectin nasal spray - Cerebrovascular Accident, Transient Ischemic Attack | Phase 2 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 60 | 2001-03-01 | 2010-05-04 |
| Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) Pirfenidone - Fibrosis, Focal Glomerulosclerosis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 21 | 1999-12-01 | 2014-05-26 |
Fibrosis (3) · Biliary Tract Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (2) · Gallbladder Neoplasms (2) · Head and Neck Neoplasms (2) · Laryngeal Diseases (2) · Squamous Cell Carcinoma of Head and Neck (2) · Astrocytoma (1) · Brain Neoplasms (1) · Demyelinating Diseases (1)
Bone Diseases (18) · Bone Diseases, Developmental (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (18) · Musculoskeletal Diseases (18) · Osteochondrodysplasias (18) · Neoplasms by Site (11) · Neoplasms (10) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (7) · Pathological Conditions, Signs and Symptoms (5) · Adenocarcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4)
pembrolizumab (3) · Losartan (2) · bintrafusp alfa protein, human (2) · Betamethasone Valerate (1) · Cisplatin (1) · Drug Delivery Systems (1) · Gemcitabine (1) · LY-2157299 (1) · Lomustine (1) · Metformin (1) · Pentoxifylline (1) · Radiotherapy (1) · Sorafenib (1) · Temozolomide (1) · Trabedersen (1)
Bicara Therapeutics (2) · EMD Serono Research & Development Institute, Inc. (2) · Eli Lilly and Company (2) · Al-Azhar University (1) · Boston Scientific Corporation (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Isarna Therapeutics GmbH (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Olivia Newton-John Cancer Research Institute (1) · Shaw Cancer Center (1) · Steadman Philippon Research Institute (1) · Weill Medical College of Cornell University (1) · Ziauddin University (1)
United States (11) · France (5) · Spain (5) · Germany (4) · Italy (4) · South Korea (4) · Taiwan (4) · Australia (3) · China (3) · Japan (3) · Poland (3) · United Kingdom (3) · Argentina (2) · Austria (2) · Belgium (2)
Alessandro M Gianni, MD (1) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Andrew M Scott, MBBS (1) · Filippo G De Braud, MD (1) · Hui K Gan, MBBS (1) · Marc J Philippon, MD (1) · Patricia H Hardenbergh, MD (1) · Silvia Formenti, M.D. (1) · Ulrich Bogdahn, MD (1)
PMID 32461347, PMID 24566706, PMID 24890385, PMID 28390753, PMID 31296256, PMID 31472446, PMID 31795071, PMID 33008091, PMID 34007848, PMID 35410255, PMID 36552855, PMID 36999533, PMID 38087967, PMID 38875119
2019 (2), 2018 (1)